This Peninsula biotech foresaw deals worth $3 billion. Now it's lining up a $57 million merger

OncoMed Pharmaceuticals Inc. — whose wide-ranging deals around cancer stem cells once promised to bring in nearly $3 billion — will merge with a London biotech company for $57.4 million, according to terms of the transaction disclosed Wednesday. The reverse merger between Redwood City-based OncoMed and Mereo BioPharma Grou p plc will give the London company a U.S. stock listing and seven experimental drugs. If the deal closes as expected in first-half 2019, it would close the books on OncoMed…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news